Galena BioPharma: Preventing Cancer Reoccurrence.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Galena BioPharma: Preventing Cancer Reoccurrence.
Released on: June 23, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Galena is an immuneo-oncology company with a unique focus on the prevention of secondary cancer reoccurrence.
  • Summary
  • Transcript
  • Participants
  • Company
Galena is an immuneo-oncology company with a unique focus on the prevention of secondary cancer reoccurrence. Mark W. Schwartz, President and CEO of Galena Biopharma, reveals how harnessing peptide immunogens to activate the patient’s immune system can combat residual cancer cells.
Galena is an immuneo-oncology company with a unique focus on the prevention of secondary cancer reoccurrence. Mark W. Schwartz, President and CEO of Galena Biopharma, reveals how harnessing peptide immunogens to activate the patient’s immune system can combat residual cancer cells.
Mark Schwartz
Galena BioPharma
Galena Biopharma, Inc. (NASDAQ: GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena’s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company’s commercial drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble Film. Collectively, Galena’s clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects.